STOCK TITAN

Vir Biotechnology adds omitted prospectus exhibit

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B5

Rhea-AI Filing Summary

Vir Biotechnology, Inc. (VIR) filed a supplement to its November 12, 2026 prospectus supplement solely to add the omitted Exhibit 107. The company stated that the supplement does not modify or update other information in the original filing.

Rule 424(b)(5) regulatory
"pursuant to Rule 424(b)(5) under the Securities Act"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-299995

SUPPLEMENT TO PROSPECTUS SUPPLEMENT DATED NOVEMBER 12, 2026

(To Prospectus dated November 12, 2026)

EXPLANATORY NOTE

Vir Biotechnology, Inc. (the “Company”) is making this filing pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended (the “Securities Act”), as a supplement to its prospectus supplement dated November 12, 2026 to the prospectus dated November 12, 2026 (the “Original Filing”), originally filed with the Securities and Exchange Commission (the “SEC”) on November 16, 2026 pursuant to Rule 424(b)(5) under the Securities Act, solely for the purpose of including Exhibit 107 required under 17 CFR § 229.601(b)(107). The Company inadvertently omitted Exhibit 107 from the Original Filing.

Except as described above, no changes have been made to the Original Filing, and this filing does not modify, amend or update any of the other information contained in the Original Filing.

Keep reading